JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

NCT07518160 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Interventions

DRUG: JS212 for Injection＋JS111 capsules (AP-L1898)

Sponsor

Shanghai Junshi Bioscience Co., Ltd.